EMA's CHMP Recommends Approval for Icotyde (icotrokinra) in Plaque Psoriasis

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Icotyde (icotrokinra). This new treatment is for adults and adolescents with plaque psoriasis, offering a potential new therapeutic option for patients.